Ibrutinib is an irreversible BTK/ITK inhibitor that is currently approved for patients with MCL who have received at least one prior therapy, CLL/SLL including those with 17p deletion, MZL who have received at least one prior anti-CD20 therapy, and Waldenstrom’s macroglobulinemia (WM) (67). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.